FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

8 results

apretude
(Cabotegravir)
ViiV Healthcare Company
Usage: APRETUDE is indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg who are at risk of HIV-1. A negative HIV-1 test is required before starting treatment.
cabenuva
(cabotegravir and rilpivirine)
ViiV Healthcare Company
Usage: CABENUVA is indicated for the treatment of HIV-1 in adults and adolescents (12 years and older, 35 kg+) as a complete regimen to replace current antiretroviral therapy in those who are virologically suppressed, with no history of treatment failure or known resistance to its components.
dovato
(dolutegravir sodium and lamivudine)
ViiV Healthcare Company
Usage: DOVATO is indicated for the treatment of HIV-1 infection in adults and adolescents (aged 12 and older, weighing at least 25 kg) either as a complete regimen for those with no prior treatment history or to replace the current regimen in virologically suppressed patients without resistance concerns.
genvoya
(elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide)
Gilead Sciences, Inc.
Usage: GENVOYA is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥25 kg) with no prior antiretroviral treatment history or to replace an existing regimen in virologically-suppressed patients on a stable regimen for at least six months without treatment failures or resistance.
isentress
(RALTEGRAVIR)
Merck Sharp & Dohme LLC
Usage: ISENTRESS® and ISENTRESS® HD are indicated for the treatment of HIV-1 infection in adults and pediatric patients, used in combination with other antiretroviral agents. ISENTRESS is for children weighing at least 2 kg, while ISENTRESS HD is for those weighing at least 40 kg.
juluca
(dolutegravir sodium and rilpivirine hydrochloride)
ViiV Healthcare Company
Usage: JULUCA is indicated for treating HIV-1 infection in virologically suppressed adults, replacing their current antiretroviral regimen. Eligible patients must have maintained suppression for at least 6 months, have no treatment failures, and no known resistance to JULUCA's components.
stribild
(elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate)
Gilead Sciences, Inc.
Usage: STRIBILD® is indicated for treating HIV-1 in adults and pediatric patients aged 12 and older (weighing at least 35 kg) without prior antiretroviral treatment or to replace a stable regimen in those virologically suppressed for at least 6 months, without resistance to its components.
triumeq
(abacavir sulfate, dolutegravir sodium, lamivudine)
ViiV Healthcare Company
Usage: TRIUMEQ and TRIUMEQ PD are indicated for the treatment of HIV-1 infection in adults and pediatric patients aged at least 3 months and weighing at least 6 kg. They are not recommended for patients with integrase resistance or suspected INSTI resistance due to insufficient dolutegravir dosage.

Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor class drugs

apretude

cabenuva

dovato

genvoya

isentress

juluca

stribild

triumeq